Britain and America have forged a key trade agreement that will preserve no duties on British pharmaceutical shipments going into the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to increase expenditure on medicines through the NHS. This pledge guarantees that tariffs on these vital goods will remain at nothing for a timeframe of three years.
This agreement is in response to earlier statements to significantly raise duties on patented drug products, with increases discussed as high as one hundred percent.
"This deal with the UK strengthens the international landscape for innovative medicines and brings long-overdue fairness to transatlantic pharmaceutical trade," an announcement declared.
Economic Significance
Drugs represent one of the the United Kingdom's largest goods shipped to the United States, which is easily the largest market for large companies like GSK and AstraZeneca.
Export figures reveal that in the year prior to September, the UK exported medicines totaling over eleven billion pounds to the US. This amount accounted for nearly one-fifth of all goods exports in that timeframe.
"This guarantee safeguards employment, increases investment and sets the stage for the UK to become a worldwide center for medical research," a minister remarked.
Key British Pledges
The agreement involves several notable changes from the United Kingdom:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new treatments to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to raise overall public funding on treatments from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The amount drug companies must refund to the NHS to stay within budget will be limited at fifteen percent. Previously, repayments were more than twenty percent.
Industry Background
The pact follows a long-running row between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
The disagreement were heightened by assertions that US consumers were charged a premium for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several significant pharmaceutical investments in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been directed toward projects in the United States.
A senior figure publicly accepted that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the previous ten-year period.
